Best Life Sciences Companies in Gaithersburg, United States
The 66 best Life Sciences companies in Gaithersburg, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Novavax.
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Gaithersburg
| # | Company | Disclosed funding | Last round | Employees | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|
| 1 | Novavax Developer of novel vaccines for the treatment of infectious diseases 83Product top 14%Patents top 17%Funding top 22%Innovation top 23% All 13 signals ▾Producttop 14% Patentstop 17% Fundingtop 22% Innovationtop 23% Partnerstop 26% Markettop 28% Moattop 29% Fin. healthtop 32% Globaltop 35% Growthtop 37% Newstop 40% Techtop 41% Talentbottom 48% Product: 4 distinct product lines · Company stage: Public Patents: 599 patents matched (strict assignee match) · 193 filings since 2022 vs 135 in 2017-21 rank vs industry peers · Fliar Intelligence Index 83/100 | $2.7B | 33 mo ago | 184 | John Jacobs President | 589 patents Formulating viral and bacterial vaccines with saponin adjuvants and nanoparticle delivery. | 2 launchs · 2 partnerships |
| 2 | Emergent BioSolutions Developer of vaccines primarily for virus infections | $491M | 45 mo ago | 1,600 1,600 → 1,366 (-15%) | — | 29 patents Vaccines and monoclonal antibodies targeting high‑risk biothreat pathogens | 1 award |
| 3 | Viela Bio Developer of biologics for treating severe inflammation and autoimmune diseases | $357M | 84 mo ago | 170 | — | 242 patents Immunomodulatory antibody/scaffold therapeutics targeting CD40L, CD19, Ilt7 for autoimmune diseases | — |
| 4 | Sirnaomics Developer of RNA based therapeutics for the treatment of cancer and fibrosis disease 80Patents top 14%Funding top 15%Innovation top 17%Growth top 28% All 9 signals ▾Patentstop 14% Fundingtop 15% Innovationtop 17% Growthtop 28% Moattop 35% Markettop 46% Talentbottom 49% Globalbottom 48% Newsbottom 21% Patents: 277 patents matched (strict assignee match) · 191 filings since 2022 vs 63 in 2017-21 Funding: Raised $267M across 14 rounds · 14 rounds over 19 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 80/100 | $267M | 9 mo ago | 88 | Patrick Lu President and CEO | 276 patents siRNA therapeutics and nanoparticle delivery systems for targeted gene silencing | 1 launch |
| 5 | VIRxSYS Developing genetic therapies for HIV and cancer | $106M | 174 mo ago | — | Riku Heikki Rautsola Ex President and CEO | 105 patents Gene therapy vectors and apoptosis-inducing biologics for cancer and genetic disease treatment | — |
| 6 | Sensei Biotherapeutics Developer of immunotherapies for the treatment of cancer | $94M | 65 mo ago | 27 | John Celebi Chief Executive Officer | 19 patents Immuno‑oncology antibodies and bispecifics targeting the VISTA checkpoint for cancer therapy | — |
| 7 | Georgiamune Developer of immunotherapeutics to treat cancer and autoimmune diseases | $75M | 34 mo ago | 14 14 → 30 (+114%) | Samir Khleif Founder & CEO | 122 patents Patents concentrated in chemistry & materials | — |
| 8 | Nuo Therapeutics Developer of regenerative products for wound care 53Growth top 11%Funding top 24%Talent top 45%Fin. health top 50% All 9 signals ▾Growthtop 11% Fundingtop 24% Talenttop 45% Fin. healthtop 50% Moatbottom 38% Globalbottom 37% Marketbottom 33% Techbottom 30% Newsbottom 21% Growth: Revenue +143% YoY · Fresh capital in last 24 mo Funding: Raised $64.6M across 18 rounds · 18 rounds over 16 yrs (1.1/yr) rank vs industry peers · Fliar Intelligence Index 53/100 | $65M | 10 mo ago | 10 10 → 19 (+90%) | David Jorden CEO & Director | — | — |
| 9 | Genvec Developer of gene-based vaccines for hearing loss and balance disorders | $62M | 158 mo ago | 16 | — | 331 patents Adenoviral vector platforms for veterinary vaccines and human gene‑therapy applications | — |
| 10 | Altimmune Developer of vaccines for infectious disease including influenza, hepatitis B and solid tumors | $58M | 71 mo ago | 17 | Vipin Garg CEO | 90 patents Vaccine and immunotherapy formulation technologies, including viral vectors, peptide vaccines, and adjuvant delivery. | — |
| 11 | Iomai Corporation Online dissertation writing help, advice, and resources for graduate students | $54M | 281 mo ago | 110 | Gerd Zettlmeissl CEO | 14 patents Transdermal vaccine delivery systems and LT‑STa fusion protein skin immunization technologies. | — |
| 12 | Zyngenia Develops monoclonal antibody (mAb)-based drugs to treat cancer, inflammation and autoimmune disorders | $43M | 165 mo ago | 6 | Carlos Barbas Founder | 37 patents Engineered multispecific peptide‑antibody complexes targeting EGFR and Ang‑2 for cancer therapy | — |
| 13 | Vtesse Pharmaceutical company focused on specialty generics and improving patient outcomes | $42M | 119 mo ago | 8 | — | 26 patents Cyclodextrin-based drug formulation excipients improving solubility and delivery. | — |
| 14 | VLP Therapeutics Developer of therapeutic vaccines for the treatment of cancer, infectious and CNS disease | $37M | 34 mo ago | 15 | Wataru Akahata Co-Founder & CEO | — | — |
| 15 | NexImmune Developer of immunotherapeutics for cancer | $36M | 88 mo ago | 69 | — | 92 patents Patents concentrated in health & consumer products | — |
| 16 | Gene Logic Integrated genomics company providing comprehensive Genomic Reference Databases and GLP compliant Microarray… | $29M | 347 mo ago | 85 | — | — | — |
| 17 | Cellective Therapeutics Biotech research company working on B Cell Research for cancer and autoimmune diseases, acquired by MedImmune… | $28M | 260 mo ago | — | Pascal Soriot CEO | — | — |
| 18 | Vector BioMed Provider of vector manufacturing solution and commercialization services | $22M | 40 mo ago | — | Boro Dropulic CEO | — | 1 launch |
| 19 | Antidote Therapeutics Developing nicotine-blockers to treat diseases caused by nicotine and addiction | $22M | 14 mo ago | 3 | Matthew Kalnik Founder & CEO | — | — |
| 20 | MaxCyte Manufacturer of electroporation systems and gene editing risk assessment services | $21M | 73 mo ago | 71 71 → 105 (+48%) | Maher Masoud Chief Executive Officer | 191 patents Patents concentrated in chemistry & materials | 1 launch · 2 partnerships |
| 21 | Valted Seq Developer of therapeutic solutions and biomarkers for treating neurodegenerative diseases | $12M | 55 mo ago | 6 | Valina Dawson Co-Founder | — | — |
| 22 | mRNA Developer of therapeutics for the treatment of cancer, rare diseases, and others | $12M | 50 mo ago | 9 | Dong Shen CEO | — | — |
| 23 | Functional Genetics Small molecule and antibody therapeutics for viral diseases | $11M | 192 mo ago | 50 | — | 90 patents Genetic perturbation platforms for antiviral target discovery and therapeutic antibody development | — |
| 24 | Propagenix Cell models and cell-based therapies using its Conditional Replication (CR) technology | $9M | 65 mo ago | 5 | — | 48 patents Scalable ex vivo expansion techniques for human epithelial cell cultures | — |
| 25 | BioLab Developer of laboratory blood tests using AI for disease detection | $5M | 204 mo ago | — | Jonathan Cohen Founder & CEO | 20 patents Advanced skin graft biomaterials and catalytic oxidation processes for medical and chemical applications | — |
| 26 | Integrated BioTherapeutics Vaccines and Antibodies for bacterial & viral infections | $5M | 37 mo ago | 43 | Javad Aman CEO | 82 patents Broad-spectrum antiviral and antibacterial immunotherapies using engineered antibodies and peptide toxins. | 1 job opening · 1 launch |
| 27 | Hememics Biotechnologies Developer of techology platform for biopreservation | $5M | 37 mo ago | 13 | Stephen Bruttig Chairman | 35 patents Multiplex point‑of‑care biosensors employing carbon‑nanotube electronic detection | — |
| 28 | Microprobes for Life Science Provider of microelectrodes and microelectrode arrays for electrophysiology studies | $4M | 81 mo ago | — | — | — | — |
| 29 | LKC Technologies Visual electrophysiology solutions for assessing retinal function in humans and animals | $4M | 36 mo ago | 35 35 → 72 (+106%) | — | 23 patents Ophthalmic electrophysiology and retinal imaging diagnostic systems | — |
| 30 | MultiplexDX Provider of solutions for the molecular diagnostics market | $3M | 41 mo ago | 35 | — | — | — |
| 31 | Primetime Life Sciences Developer of translational medicine | $3M | 81 mo ago | — | Janak Padia President & CEO | — | — |
| 32 | DFH Pharma Developer of pharmaceutical products, focusing on drug development and medical trends | $2M | 8 mo ago | — | Carl Wild Founder & CEO | — | — |
| 33 | MedImmune Biologic R&D for oncology; respiratory, inflammation and autoimmune; and cardiovascular and metabolic diseases | $2M | 93 mo ago | 3,000 | Speck Loe CEO | 3,933 patents Therapeutic antibodies, bispecifics, and ADCs targeting immune receptors for inflammation and cancer | — |
| 34 | Amplexd Therapeutics Developer of therapeutics to treat cervical cancer | $2M | 25 mo ago | — | Reid von Borstel Co-Founder | — | — |
| 35 | NeoDiagnostix Limited information available | $2M | 207 mo ago | — | Richard Pinnola CEO | 32 patents Automated image analysis for cervical cytology and cancer cell diagnostics | — |
| 36 | Otomagnetics Developing non-invasive magnetic drug delivery technology for targeted therapies | $1M | 99 mo ago | 10 | Abhita Vohra Co-Founder & CEO | 50 patents Targeted magnetic drug delivery and magnetic therapy devices for ear and skin | — |
| 37 | ConverGene Developing dual inhibitors for rare diseases and cancer therapies | $850K | 146 mo ago | 5 | — | 54 patents Design and synthesis of bromodomain‑targeting small‑molecule therapeutics for epigenetic modulation | — |
| 38 | Fidelity Systems Developer of tools for advanced DNA and protein technologies | $539K | 205 mo ago | — | Michael Fidelis CEO | — | — |
| 39 | TeraImmune Developer of cell therapies for treating different diseases | $225K | 98 mo ago | 10 | Jihoon Park Co-Founder & COO | 11 patents Cellular immunotherapy using cord‑blood‑derived regulatory T cells and enhanced stem‑cell combos for dermatitis | — |
| 40 | EdgeBio Manufacturer and distributor for DNA sequencing and purification | $109K | 191 mo ago | 11 | — | — | — |
Top 12 Life Sciences companies in Gaithersburg
#1
Public · Gaithersburg, Maryland · founded 2007 · 88 employees$267Mraised▾
Developer of RNA-based therapeutics for the treatment of cancer and fibrosis disease. The company has proprietary delivery technologies, a polypeptide nanoparticle RNAi platform and GalNAc RNAi platform, GalAhead, to develop drug candidate pipeline which include STP122G for cardiovascular disease treatment. It also, develops pipeline of drugs for cancers, skin conditions, fibrosis-related diseases, antiviral and cardiometabolic diseases, and medical aesthetics.
- Sep 2025Post IPO$17.7M
- Jul 2021Series E$105M
- Oct 2020Series D$105M
- Jul 2019Series C$25M
#2
Public · Gaithersburg, Maryland · founded 2001 · 10 employees$64.6Mraised▾
Developer of regenerative products for wound care. The company focuses on regenerative therapies to primarily address the areas of wound care, inflammation, and angiogenesis. Its proprietary technology Aurix is a biodynamic hematogel that is an auto platelet and plasma therapy system. It has been approved by the FDA for use in the management of wounds and ulcers of all types and severities.
- Jul 2025Post IPO$791.4K
- Sep 2024Post IPO$849.1K
- May 2024Post IPO$650.9K
- Dec 2023Post IPO$962.5K
#3
Funding Raised · Gaithersburg, Maryland · founded 2017 · 3 employees$22.4Mraised▾
Developing nicotine-blockers to treat diseases caused by nicotine and addiction. The company is focused on creating first-in-class treatments targeting rare vascular diseases and addiction through proprietary treatments. They leverage a global collaborative drug research and development network, incorporating expertise from academic labs, clinical research groups, biotechnology companies, and biopharmaceutical consultants. Their pipeline includes a fully human, anti-nicotine monoclonal antibody and a nicotine-degrading enzyme, both in development. The company aims to address the global health crisis related to smoking by providing innovative therapeutic solutions. This involves immunotherapeutic approaches, clinical research, and biopharmaceutical drug development.
- Apr 2025Grant (prize money)$13.1M
- Sep 2017Grant (prize money)$8.5M
- Sep 2017Conventional Debt$200K
- Aug 2017Conventional Debt$432.3K
#4
Funding Raised · Gaithersburg, Maryland · founded 2011$2.3Mraised▾
Developer of pharmaceutical products, focusing on drug development and medical trends. The company strives to improve patient health within the healthcare industry. Its team monitors medical advancements and technology. The company focuses on finding better methods in an evolving industry.
- Sep 2025Grant (prize money)$986.9K
- Jul 2020Grant (prize money)$943.1K
- Sep 2018Grant (prize money)$171.5K
- Aug 2013Grant (prize money)$186.4K
#5
Public · Gaithersburg, Maryland · founded 1987 · 184 employees$2.7Braised▾
Developer of novel vaccines for the treatment of infectious diseases. Its pipeline includes a vaccine for respiratory syncytial virus infection, coronavirus, malaria, ebola, and seasonal quadrivalent vaccines for influenza. It uses recombinant nanoparticles and adjuvant technology.
- Sep 2023Post IPO$84.5M
- Jul 2020Grant (prize money)$1.6B
- Jun 2020Post IPO$200M
- Jun 2020Grant (prize money)$60M
#6
Public · Gaithersburg, Maryland · founded 1998 · 1600 employees$490.9Mraised▾
Developer of vaccines primarily for virus infections. The lead candidate NuThrax, a vaccine in combination with a novel immunostimulatory compound CPG 7909 is for anthrax. Also, has PreviThrax, a vaccine in phase 1 trials for anthrax, VAX161C, a recombinant Hemagglutinin influenza subunit antigen - bacterial flagellin fusion protein H5 influenza vaccine for pandemic influenza and UV-4B, and an antiviral iminosugar in phase 1 trials for dengue virus infections. The company also offers CMO services for both bulk drug substances and sterile injectable drug products.
- Sep 2022Grant (prize money)$385K
- Apr 2020Grant (prize money)$14.5M
- Feb 2020Post IPO$32K
- Sep 2019Grant (prize money)$6.3M
#7
Series A · Gaithersburg, Maryland · founded 2019 · 14 employees$75Mraised▾
Developer of immunotherapeutics to treat cancer and autoimmune diseases. The company focused on reprogramming immune signaling pathways to redirect the immune system to fight diseases such as cancer and autoimmune diseases. The company's pipeline includes GIM-122 a dual-functioning antibody, GIM-531 treg inhibitor to restore antitumor effects, and GIM-407 Treg Activator for autoimmune diseases.
- Aug 2023Series A$75M
#8
Series A · Gaithersburg, Maryland · founded 2012 · 15 employees$37Mraised▾
Developer of therapeutic vaccines for the treatment of cancer, infectious, and CNS diseases. Its drug pipeline includes VLPM01, a pre-erythrocytic vaccine that targets the CSP antigen of P. falciparum sporozoites, and a preventive vaccine for dengue. Also developing a therapeutic vaccine for Breast, Lung, Prostate Cancer; vaccines for Alzheimer's, Schizophrenia.
- Aug 2023Series A—
- Dec 2021Series A$21M
- Mar 2021Series A$16M
- Dec 2018Grant (prize money)$3.9M
#9
Acquired · Gaithersburg, Maryland · founded 2017 · 170 employees$357.3Mraised▾
Developer of biologics for treating severe inflammation and autoimmune diseases. Their lead candidate inebilizumab, which is indicated for Neuromyelitis Optica Spectrum Disorder. Other candidates include HZN-825 for diffuse cutaneous systemic sclerosis, HZN-4920 for Sjögren’s syndrome, rheumatoid arthritis, kidney transplant, and others. It is a humanized monoclonal antibody that binds and depletes CD19+ B cells including plasmablasts and plasma cells.
- Jun 2019Series B$75M
- Feb 2018Series A$282.3M
#10
Public · Gaithersburg, Maryland · founded 1999 · 27 employees$93.5Mraised▾
Developer of immunotherapies for the treatment of cancer. The company has proprietary immuno-oncology technology platform, SPIRIT, which helps in immune recognition. It has developed SNS-301iImmunoPhage that has dose-dependent antigen-specific CD8+ T cell and B-cell response for head and neck cancer patients.
- Jan 2021Series B$30M
- Oct 2020Unattributed$28.5M
- Jan 2020Unattributed$25M
- Dec 2015Unattributed$15M
#11
Series B · Gaithersburg, Maryland · founded 2021$22.5Mraised▾
Provider of vector manufacturing solution and commercialization services
- Jan 2023Series B$15M
- Dec 2022Series A$7.5M
#12
Seed · Gaithersburg, Maryland · founded 2022$2Mraised▾
Developer of therapeutics to treat cervical cancer. The company has developed two topical, non-invasive early cervical cancer treatments for low-grade dysplasia and invasive surgeries for high-grade dysplasia and it mainly focuses on HPV-induced early cervical cancers.
- May 2024Seed$2M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in the United States
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 6,260 United States-affiliated papers.
- Harvard University209
- Cornell University177
- University of Tennessee at Chattanooga140
- Howard Hughes Medical Institute126
- Johns Hopkins University121
- Gene33→164
- Transcription (linguistics)11→79
- Antibody11→62
- Genome6→56
- Mutation7→56
- Gene8→110
- Cell culture3→62
- Gene expression3→62
- Fermentation2→54
- Downregulation and upregulation1→50
- Agriculture19→58
- Antibiotic resistance15→45
- Public health4→31
- Gene6→30
- Production (economics)5→29
Where biotechnology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing biotechnology patents in the United States
United States biotechnology patent filing is accelerating — 457,918 filings from 8,000 assignees (2016–2025), led by Genentech, UNIV California, Regeneron Pharma; annual filings 36884→44446.
- Genentech18078
- UNIV California17948
- Regeneron Pharma16082
- Amgen10495
- Monsanto Technology9742
- UNIV Pennsylvania8521
- Harvard College7460
- UNIV Texas7378
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.